Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01314313 · ClinicalTrials.gov registry record · NA

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk

A NA study, sponsored by Edwards Lifesciences.

Completed
Registry status
NA
Development phase
2,032
Enrollment target

NCT01314313: Completed NA study, sponsored by Edwards Lifesciences.

NCT01314313 is a NA study that has completed, run by Edwards Lifesciences. The registered enrollment target is 2,032 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (45% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01314313, a NA study, has completed, sponsored by Edwards Lifesciences.

COMPLETED
Registry status
NA
Development phase
2,032 participants
Enrollment target

Study Summary

The purpose of this trial is to determine the safety and effectiveness of the Edwards SAPIEN XT transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, severe aortic stenosis.

Primary Outcome

All-cause Death or Disabling Stroke (Edwards SAPIEN XT THV vs SAVR)

Interventions

  • DEVICE TAVR Implantation with SAPIEN XT
  • DEVICE SAVR Implantation

Trial Details

FieldValue
Enrollment Target 2,032 participants
Start Date 2011-03
Est. Completion 2024-01-17
Phase NA
Edwards Lifesciences

57 total trials

What the finished NCT01314313 record still lists

NCT01314313 is an interventional study that assigns participants to a tested intervention. Its 2,032 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (45% higher).

The record links to 0 conditions, and to 2 interventions - of which TAVR Implantation with SAPIEN XT is the first listed.

NCT01314313 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01314313 about?

NCT01314313 is a clinical study titled "PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk". The purpose of this trial is to determine the safety and effectiveness of the Edwards SAPIEN XT transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, severe aortic stenosis.

What is the current status of trial NCT01314313?

This trial is currently completed. It is a NA study. The enrollment target is 2,032 participants. The study started on 2011-03. Estimated completion is 2024-01-17.

What interventions are being tested in trial NCT01314313?

The interventions under investigation include: TAVR Implantation with SAPIEN XT (DEVICE), SAVR Implantation (DEVICE).

Who is sponsoring clinical trial NCT01314313?

This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01314313's enrollment target sits among peer trials

2,032 52nd of 2000 higher than 1,949 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05625659 · 2,032 participants · NA

    Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

  • NCT04216732 · 2,030 participants

    Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management

  • NCT06825897 · 2,039 participants · NA

    Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe

  • NCT05138718 · 2,041 participants

    FDG an Myocardial Infarction: The PIAF Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01314313, the US trial registry maintained by the National Library of Medicine. NCT01314313 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.